Go to deals
Healthcare | Private Equity

LDI has sold UltiMed to Levine Leichtman Capital Partners

UltiMed, Inc., a portfolio company of LDI, Ltd., has been sold to an investment vehicle sub-managed by Levine Leichtman Capital Partners, LLC.

UltiMed’s insulin pen needles, syringes and complementary products are critical offerings for diabetes patients who need daily insulin injections and for companion animals who increasingly suffer from this life-threatening disease. UltiMed’s proprietary “dispense and dispose” solutions provide diabetes patients a safe and convenient way to store used sharps following injection.

Levine Leichtman Capital Partners is a private equity and venture capital firm specializing in acquisitions, buyouts, recapitalizations, refinancing, balance sheet restructuring, growth financing, structured equity, distressed debt, leveraged loan and mezzanine investments in the middle market.

LDI, Ltd. is a private equity firm specializing in investing in acquisitions and add-on acquisitions. It is a family office based in Indianapolis, IN, with more than a century of experience funding and operating high-potential, middle-market companies.

One of Oaklins’ teams in the USA served as the exclusive financial advisor to UltiMed, Inc., a portfolio company of LDI, Ltd., in this transaction.

Parties
“We selected the team based on their prior experience with UltiMed and their expertise in transactions in the diabetes and animal health sectors. They did an outstanding job of presenting UltiMed’s many strengths and growth opportunities to the market, and their deep relationships with potential acquirors were key to our success. We particularly appreciate the senior team focus they brought to completing this transaction despite the emergence of the COVID-19 pandemic in the midst of this assignment.”

John Martin

VP Corporate Development, LDI, Ltd.

Talk to the deal team

 Michael S. Goldman

Michael S. Goldman

Managing Director
New York, United States
Oaklins TM Capital
 Steve  Hunter

Steve Hunter

Managing Director
Atlanta, United States
Oaklins TM Capital
 James  McLaren

James McLaren

Managing Director
New York, United States
Oaklins TM Capital
 John  Dean

John Dean

Associate Director
Atlanta, United States
Oaklins TM Capital

Related deals

Perkbox has been acquired by Great Hill Partners
Private Equity | TMT

Perkbox has been acquired by Great Hill Partners

Molten Ventures has sold Perkbox to Great Hill Partners.

Learn more
Arculus Cyber Security has been acquired by Bridewell
Private Equity | TMT

Arculus Cyber Security has been acquired by Bridewell

The shareholders of Arculus Cyber Security (Arculus) have sold the business to Bridewell. The deal will bolster Bridewell’s growing roster of accreditations as well as strengthen its public sector footprint, enabling the expansion of its end-to-end cyber security offering for clients across the globe.

Learn more
Prestige Inhome Care has found a long-term strategic partner
Healthcare

Prestige Inhome Care has found a long-term strategic partner

Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.

Learn more